NFKB cRel Peptide, Rockland ImmunochemicalsSupplier: Rockland Immunochemical
RL100-4166PEA 148.29 USDRL100-4166P
NFKB cRel Peptide, Rockland Immunochemicals
Proteins and Peptides
NFKB cRel Control Peptide
- Control Peptide - Blocking Peptide
- PCA Assays
Intended for use as a control peptide when used with anti-NFkB cRel to block specific interaction of anti-NFkB cRel (p/n 100-4166) with the NFkB cRel subunit. NFkB was originally identified as a factor that binds to the immunoglobulin kappa light chain enhancer in B cells. It was subsequently found in non-B cells in an inactive cytoplasmic form consisting of NFkB bound to IkB. NFkB was originally identified as a heterodimeric DNA binding protein complex consisting of p65 (RelA) and p50 (NFKB1) subunits. Other identified subunits include p52 (NFKB2), c-Rel, and RelB. The p65, cRel, and RelB subunits are responsible for transactivation. The p50 and p52 subunits possess DNA binding activity but limited ability to transactivate. p52 has been reported to form transcriptionally active heterodimers with the NFkB subunit p65, similar to p50/p65 heterodimers. The heterodimers of p52/p65 and p50/p65 are regulated by physical inactivation in the cytoplasm by IkB-a. IkB-a binds to the p65 subunit, preventing nuclear localization and DNA binding. Low levels of p52 and p50 homodimers can also exist in cells.
Control peptide should be used at 1.0 µg per 1.0 µl of antiserum in per assay.